Home › Cancer (all types) › NCT05324553

Patient Derived Preclinical Models

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* 18 years of age and older
* Patient is a good medical candidate for a standard of care or research biopsy or surgical procedure to obtain tissue

Exclusion Criteria:

* Uncontrolled concurrent illness including psychiatric illness, or situations that would limit compliance with the study requirements or the ability to willingly give written informed consent
* Institutionalized or incarcerated patients
* Inaccessible tumor for biopsy or patient does not have tumor tissue available for research use
* Biopsy must not be considered more than minimal risk to the patient.
* Have a contraindication to percutaneous biopsy including:

  1. Significant coagulopathy that cannot be adequately corrected.
  2. Severely compromised cardiopulmonary function or hemodynamic instability.
  3. Lack of a safe pathway to the lesion per the interventional radiologist.
  4. Inability of the patient to cooperate with, or to be positioned for, the procedure.

About the study

Study goal is to collect tumor specimens that may inform cancer biology to eventually improve outcomes for patients with cancer. This proposal represents a highly collaborative effort to support cancer research with the goal of developing novel therapeutic strategies using patient derived preclinical models.

This study is being done to collect samples of tumor tissues, matched normal tissue when possible, and approximately 50 mL of blood.

What is being tested

• Tissue Collection (procedure)
• Blood Collection (diagnostic test)
• Buccal Swab (diagnostic test)

Sponsor: Mayo Clinic · Participants: 50 · Started: Apr 6, 2022

Contact the study team

• Clinical Trials Referral Office · Phone: 855-776-0015
• Tanya M. Schnick · Phone: 507 293-7582

Official record on ClinicalTrials.gov — NCT05324553

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.